Details of the Drug

General Information of Drug (ID: DMQR4HA)

• Drug Name: DABIS MALEATE
• Synonyms: E-83-041; 1,4-Bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane dimaleate

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 340.2
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 5
  Hydrogen Bond Donor Count; 1
  Hydrogen Bond Acceptor Count; 4
• Chemical Identifiers:
  Formula: C13H21Cl2N2O4+
  IUPAC Name: 1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane;(Z)-4-hydroxy-4-oxobut-2-enoate
  Canonical SMILES: C1C[N+]2(CC[N+]1(C2)CCCl)CCCl.C(=C\\C(=O)[O-])\\C(=O)O
  InChI: InChI=1S/C9H18Cl2N2.C4H4O4/c10-1-3-12-5-7-13(9-12,4-2-11)8-6-12;5-3(6)1-2-4(7)8/h1-9H2;1-2H,(H,5,6)(H,7,8)/q+2;/p-1/b;2-1-
  InChIKey: HKVBKOPISPWMSR-BTJKTKAUSA-M
• Cross-matching ID:
  PubChem CID: 54599345
  CAS Number: 73387-70-9
  TTD ID: D09URP

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[2]

References

• [1] Phase I study of DABIS maleate given once every 3 weeks. Eur J Cancer. 1991;27(12):1635-7.
• [2] DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9.